📊 IOSP Key Takeaways
Is IOSP a Good Investment? Thesis Analysis
Innospec demonstrates solid financial health with exceptional liquidity (2.79x current ratio), zero long-term debt, and strong free cash flow generation ($120.7M). While revenue declined 3.7% YoY, the dramatic 227.5% net income surge indicates significant operational leverage and margin improvement, though sustainability of this exceptional earnings growth requires scrutiny.
Why Buy IOSP? Key Strengths
- Zero long-term debt with $292.5M cash provides financial flexibility and fortress balance sheet
- Exceptional free cash flow conversion (6.8% FCF margin on declining revenue) demonstrates efficient capital management
- Net income growth of 227.5% YoY with EPS up 228.9% suggests operational turnaround and margin expansion
- Strong liquidity position (2.79x current ratio, 1.88x quick ratio) ensures operational stability
IOSP Investment Risks to Consider
- Revenue decline of 3.7% YoY in cyclical chemicals sector raises concerns about end-market demand and competitive position
- Net margin of only 6.6% and operating margin of 7.3% are modest for a company claiming significant operational improvement
- Exceptional earnings growth appears anomalous relative to flat/declining revenue, suggesting one-time items or unusual gains requiring validation
- High insider trading activity (27 Form 4 filings in 90 days) warrants investigation for potential signaling concerns
Key Metrics to Watch
- Revenue growth trajectory and segment-level performance to confirm end-market stabilization
- Sustainability of margin improvements and verification of earnings quality (operating vs. non-operating gains)
- Capital expenditure trends and R&D spending to assess competitive investment levels
- Working capital efficiency and free cash flow consistency in subsequent quarters
IOSP Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.79x current ratio provides a solid financial cushion.
IOSP Profitability Ratios
IOSP vs Default Sector
How INNOSPEC INC. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IOSP Overvalued or Undervalued?
Based on fundamental analysis, INNOSPEC INC. has mixed fundamental signals relative to the Default sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IOSP Balance Sheet & Liquidity
IOSP 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: INNOSPEC INC.'s revenue has grown significantly by 29% over the 5-year period, indicating strong business expansion. The most recent EPS of $5.56 reflects profitable operations.
IOSP Growth Metrics (YoY)
IOSP Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $441.9M | $12.9M | $0.52 |
| Q2 2025 | $435.0M | $23.5M | $0.94 |
| Q1 2025 | $440.8M | $32.8M | $1.31 |
| Q3 2024 | $443.4M | $33.4M | $1.33 |
| Q2 2024 | $435.0M | $28.9M | $1.16 |
| Q1 2024 | $500.2M | $33.2M | $1.33 |
| Q3 2023 | $464.1M | $38.7M | $1.55 |
| Q2 2023 | $467.6M | $28.9M | $1.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IOSP Capital Allocation
IOSP SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for INNOSPEC INC. (CIK: 0001054905)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IOSP
What is the AI rating for IOSP?
INNOSPEC INC. (IOSP) has an AI rating of BUY with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IOSP's key strengths?
Claude: Zero long-term debt with $292.5M cash provides financial flexibility and fortress balance sheet. Exceptional free cash flow conversion (6.8% FCF margin on declining revenue) demonstrates efficient capital management.
What are the risks of investing in IOSP?
Claude: Revenue decline of 3.7% YoY in cyclical chemicals sector raises concerns about end-market demand and competitive position. Net margin of only 6.6% and operating margin of 7.3% are modest for a company claiming significant operational improvement.
What is IOSP's revenue and growth?
INNOSPEC INC. reported revenue of $1.8B.
Does IOSP pay dividends?
INNOSPEC INC. pays dividends, with $42.4M distributed to shareholders in the trailing twelve months.
Where can I find IOSP SEC filings?
Official SEC filings for INNOSPEC INC. (CIK: 0001054905) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IOSP's EPS?
INNOSPEC INC. has a diluted EPS of $4.67.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IOSP a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, INNOSPEC INC. has a BUY rating with 72% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is IOSP stock overvalued or undervalued?
Valuation metrics for IOSP: ROE of 8.8% (sector avg: 15%), net margin of 6.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IOSP stock in 2026?
Our dual AI analysis gives INNOSPEC INC. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IOSP's free cash flow?
INNOSPEC INC.'s operating cash flow is $138.3M, with capital expenditures of $17.6M. FCF margin is 6.8%.
How does IOSP compare to other Default stocks?
Vs Default sector averages: Net margin 6.6% (avg: 12%), ROE 8.8% (avg: 15%), current ratio 2.79 (avg: 1.8).